SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-351634"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-351634" > Antithrombotic ther...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005359naa a2200505 4500
001oai:DiVA.org:uu-351634
003SwePub
008180607s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3516342 URI
0247 a https://doi.org/10.1093/ehjcvp/pvy0022 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Goto, Shinyau Tokai Univ, Sch Med, Dept Med Cardiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.4 aut
2451 0a Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation :b insights from ARISTOTLE
264 c 2018-01-29
264 1b Oxford University Press (OUP),c 2018
338 a print2 rdacarrier
520 a Aims We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study to better inform the care of these high-risk patients. Method and results Thrombo-embolic events were defined as stroke (ischaemic or unknown cause) or systemic embolism (SE). Clinical outcomes were estimated using the Kaplan-Meier method. All-cause mortality and International Society on Thrombosis and Haemostasis (ISTH) major bleeding after events were analysed using a Cox proportional hazards model with time-dependent covariates. Of 18 201 patients in ARISTOTLE, 365 experienced a thrombo-embolic event [337 strokes (ischaemic or unknown cause), 28 SE]; 46 (12.6%) of which were fatal. In the 30 days before and after a thrombo-embolic event, 11% and 37% of patients, respectively, were not taking an oral anticoagulant. During follow-up (median 1.8 years), 22 patients (7.1%/year) had a recurrent stroke, 97 (30.1%/year) died, and 10 (6.7%/year) had major bleeding. Compared with patients without a thrombo-embolic event, the short-and long-term adjusted hazards of death in patients with a thrombo-embolic event were high [<= 30 days: hazard ratio (HR) 54.3%, 95% confidence interval (95% CI) 41.4-71.3; >30 days: HR 3.5, 95% CI 2.5-4.8; both P<0.001]. The adjusted hazards of major bleeding were also high short-term (HR 10.37, 95% CI 3.87-27.78; P<0.001) but not long-term (HR 1.7, 95% CI: 0.77-3.88; P=0.18). Conclusions Thrombo-embolic events were rare but associated with high short-and long-term morbidity and mortality. Substantial numbers of patients are not receiving oral anticoagulattherapy before and, despite this risk, after a first thrombo-embolic event.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Antithrombotic therapy
653 a Thrombo-embolic events
653 a Atrial fibrillation
7001 a Merrill, Peteru Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 aut
7001 a Wallentin, Lars,d 1943-u Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall
7001 a Wojdyla, Daniel M.u Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 aut
7001 a Hanna, Michaelu Bristol Myers Squibb, 3551 Lawrenceville Princeton, Lawrence Township, NJ 08648 USA.4 aut
7001 a Avezum, Alvarou Dante Pazzanese, Inst Cardiol, Res Div, Ave Dante Pazzanese 500, BR-04012909 Sao Paulo, SP, Brazil.4 aut
7001 a Easton, J. Donaldu Univ Calif San Francisco, Dept Neurol, Box 0663,675 Nelson Rising Lane,412, San Francisco, CA 94158 USA.4 aut
7001 a Harjola, Veli-Pekkau Univ Helsinki, Cent Hosp, Dept Med, Div Emergency Care, POB 340, Helsinki 00029, Hus, Finland.4 aut
7001 a Huber, Kurtu Med Univ Vienna, Wilhelminenspital, Dept Cardiol, Spitalgasse 23, A-1090 Vienna, Austria.4 aut
7001 a Lewis, Basil S.u Technion, Ruth & Bruce Rappaport Sch Med, Lady Davis Carmel Med Ctr, Dept Cardiol, Mikhal St 7, IL-3436212 Haifa, Israel.4 aut
7001 a Parkhomenko, Alexanderu Inst Cardiol, Dept Cardiol, Narodnoho Opolchennya St 5, UA-02000 Kiev, Ukraine.4 aut
7001 a Zhu, Junu Fuwai Hosp, Beijing, Peoples R China.4 aut
7001 a Granger, Christopher B.u Duke Hlth, Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27705 USA.4 aut
7001 a Lopes, Renato D.u Duke Hlth, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.4 aut
7001 a Alexander, John H.u Duke Hlth, Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27705 USA.4 aut
7102 a Tokai Univ, Sch Med, Dept Med Cardiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.b Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 org
7730 t European Heart Journal - Cardiovascular Pharmacotherapyd : Oxford University Press (OUP)g 4:2, s. 75-81q 4:2<75-81x 2055-6837x 2055-6845
8564 u https://academic.oup.com/ehjcvp/article-pdf/4/2/75/24260579/pvy002.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351634
8564 8u https://doi.org/10.1093/ehjcvp/pvy002

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy